Evidence map›Paper›PMID 18491370›Full record

ArticleThe Prostate2008

Inhibitory effects of nordihydroguaiaretic acid (NDGA) on the IGF-1 receptor and androgen dependent growth of LAPC-4 prostate cancer cells.

Charles J Ryan, Marianna Zavodovskaya, Jack F Youngren, Michael Campbell, Marc Diamond, Jeremy Jones, Laura Shiry, Geoffrey Allan, Betty A Maddux, Ira D Goldfine

Open access · greenAbstract read
In one paragraph

Article in The Prostate, 2008. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
0.9field-weighted citation impact, top 23% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 18 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 3 institutions in 1 country.

Charles J RyanDepartment of Medicine, University of California, San Francisco, California 94143, USA. ryanc@medicine.ucsf.edu
Marianna Zavodovskaya
Jack F Youngren
Michael Campbell
Marc Diamond
Jeremy Jones
Laura Shiry
Geoffrey Allan
Betty A Maddux
Ira D Goldfine
University of California, San Francisco · USInsmed (United States) · USUCSF Helen Diller Family Comprehensive Cancer Center · US

Funding

Targeting Androgen -IGF Interactions in Prostate CancerK23CA115775 · NCI · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI RYAN, CHARLES JAMES · 2005 to 2009
$640k
NCI NIH HHS K23 CA115775NCI NIH HHS K23CA115775
6 · The paper itself

Abstract

backgroundNordihydroguaiaretic acid (NDGA) is an inhibitor of the IGF-1 receptor (IGF-1R) in breast and other cancers, and concomitantly inhibits tumor growth both in cultured cells and animals. The current study evaluates the effect of NDGA on the androgen-stimulated growth of human prostate cancer cells.

methodsLAPC-4 prostate cancer cells in tissue culture were androgen starved for 3 days, 1 nM dihydrotestosterone (DHT) and other androgens were then added for up to 7 days, and cell proliferation measured. IGF-1R protein expression was measured by Western blot, and IGF-1R mRNA expression by quantitative PCR. IGF-1R receptor kinase activation was measured by ELISA.

resultsAfter 7 days, LAPC-4 growth was doubled by 1 nM DHT. NDGA had a rapid effect to inhibit IGF-1R autophosphorylation induced by IGF-1. DHT increased the expression of IGF-1R protein and mRNA levels. Maximal IGF-1R protein levels were observed 3 days after the addition of androgen. In addition, NDGA, at 10 microM or less, inhibited DHT-induced proliferation in both cells grown in plates and cells grown in soft agar. Androgen receptor (AR) studies by FRET revealed that NDGA had no conformational effects on the AR in response to ligand.

conclusionsNDGA blocks the DHT-induced growth of LAPC-4 prostate cancer cells by several mechanisms including rapid inhibition of the IGF-1R kinase, and a dose-dependent inhibition of androgen stimulation of IGF-1R expression. Clinical studies of this agent will determine its efficacy in the setting of androgen-dependent prostate cancer.

Indexed as

AntioxidantsCell DivisionCell Line, TumorDihydrotestosteroneDose-Response Relationship, DrugDrug InteractionsGene Expression Regulation, NeoplasticHumansMaleMasoprocolPhosphorylationProstatic NeoplasmsProtein ConformationReceptor, IGF Type 1Receptors, AndrogenReverse Transcriptase Polymerase Chain ReactionAntioxidantsDihydrotestosteroneMasoprocolReceptor, IGF Type 1Receptors, AndrogenRNA, Messenger

Identifiers

PMID18491370
PMCPMC7305632
OpenAlexW4248466837

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.